处理不确定的 SARS-CoV-2 PCR 样本-我们的经验。
Dealing with inconclusive SARS-CoV-2 PCR samples-Our experience.
机构信息
Department of Microbiology and Virology, Medical University Varna, Varna, Bulgaria.
Laboratory of Virology, University Hospital "St. Marina", Varna, Bulgaria.
出版信息
PLoS One. 2022 May 13;17(5):e0268187. doi: 10.1371/journal.pone.0268187. eCollection 2022.
PURPOSE
Early confirmation of SARS-CoV-2 is a key point in the timely management of infected patients and contact persons. Routine diagnostics of COVID-19 cases relies on RT-PCR detection of two or three unique sequences of the virus. A serious problem for the laboratories is how to interpret inconclusive samples which are positive for only one of the SARS-CoV-2 specific genes.
MATERIALS AND METHODS
A total of 16364 naso-oropharyngeal swabs were collected and tested with SARS-CoV-2 Real-TM kit (Sacace Biotechnologies, Italy) between May and September 2020. We retrospectively analyzed their amplification plots to determine the number of inconclusive samples. We also reviewed the medical records to summarize the patient's COVID-19 testing history and basic demographic characteristics.
RESULTS
We obtained 136 (0.8%) inconclusive samples with amplification signal only for the N-gene. Thirty-nine of the samples were excluded from further analysis as no additional data were available for them. Of the rest of the samples, the majority- 48% (95% CI 38-59%) had a previous history of SARS-CoV-2 positivity, 14% (95% CI 8-23%)-a subsequent history of positivity and 37% (95% CI 28-48%) were considered as false positive.
CONCLUSION
A substantial proportion of the inconclusive results should be considered as positive samples at the beginning or the end of the infection. However, the number of false-positive results is also significant and each patient's result should be analyzed separately following the clinical symptoms and epidemiological data.
目的
及早确认 SARS-CoV-2 是及时管理感染患者和接触者的关键。COVID-19 病例的常规诊断依赖于 RT-PCR 检测病毒的两个或三个独特序列。实验室面临的一个严重问题是如何解释仅一个 SARS-CoV-2 特异基因呈阳性的不确定样本。
材料与方法
2020 年 5 月至 9 月期间,我们共采集并使用 SARS-CoV-2 Real-TM 试剂盒(Sacace Biotechnologies,意大利)检测了 16364 例鼻咽拭子。我们回顾性分析了它们的扩增图谱,以确定不确定样本的数量。我们还查阅了病历,总结了患者的 COVID-19 检测史和基本人口统计学特征。
结果
我们获得了 136 份(0.8%)仅 N 基因扩增信号不确定的样本。由于这些样本没有其他可用数据,因此其中 39 份被排除在进一步分析之外。在其余样本中,大多数(48%(95%CI 38-59%))有 SARS-CoV-2 阳性史,14%(95%CI 8-23%)有随后的阳性史,37%(95%CI 28-48%)被认为是假阳性。
结论
大量不确定结果应被视为感染开始或结束时的阳性样本。然而,假阳性结果的数量也很显著,应根据临床症状和流行病学数据单独分析每个患者的结果。